In Brief: Medtronic/EchoCath
This article was originally published in The Gray Sheet
Medtronic/EchoCath: Firms' second licensing agreement gives Medtronic exclusive rights to employ EchoCath's EchoMark and ColorMark technologies for guiding Medtronic's Grinfield cannula aortic clamp, as well as a six-month period to evaluate future licensing of EchoCath's EchoFlow and EchoEye cardiovascular technologies. In exchange, Medtronic pays a total of $1.8 mil. -- representing licensing fees and the acquisition of $1 mil. in restricted shares of EchoCath Class A common stock. EchoMark and ColorMark aid guidance of cardiovascular devices, such as cannulas, by using existing ultrasound equipment, eliminating the need for x-ray confirmation of device positioning, EchoCath says. The firms' first alliance was formed in December 1996 to develop an ultrasound-guided heart pacemaker lead implantation system...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.